Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.33 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.31 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.31 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL360638 | 0.93 | GPR84 (0.34) | MEN1HTTKMT2AL3MBTL1CAMK2A | |
| SCHEMBL11060568 | 0.91 | FFAR1 (0.38) | MEN1HTTKMT2AL3MBTL1CAMK2A | |
| SCHEMBL15263236 | 0.91 | FFAR1 (0.38) | MEN1HTTKMT2AL3MBTL1CAMK2A | |
| SCHEMBL319857 | 0.86 | MEN1 (0.35) | MEN1HTTKMT2AL3MBTL1 | |
| SCHEMBL21069916 | 0.85 | CYP4F2 (0.38) | — | |
| SCHEMBL15569600 | 0.82 | MEN1 (0.33) | MEN1HTTKMT2AL3MBTL1 | |
| SCHEMBL10830752 | 0.82 | CA12 (0.40) | MEN1KMT2AGPR84FFAR1FFAR4 | |
| SCHEMBL19025042 | 0.82 | FOLH1 (0.36) | MEN1HTTKMT2AL3MBTL1 | |
| Hydroxyamine SCHEMBL30884523 | 0.82 | MEN1 (0.33) | MEN1HTTKMT2AL3MBTL1 | |
| SCHEMBL17093613 | 0.81 | KDM4A (0.39) | MEN1HTTKMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12558345-B2 | CHK1/2 inhibitors for use in the treatment of neuroblastomas and/or soft tissue sarcomas | ELI LILLY AND COMPANY (US) | 2026-02-24 | — | — | US | disclosed |
| US-20260022109-A1 | 5-HETEROARYL-1H-PYRAZOL-3-AMINE DERIVATIVE | Sumitomo Pharma Co., Ltd. (JP) | 2026-01-22 | — | — | US | disclosed |
| US-20250352541-A1 | THERAPEUTIC FOR CANCER REFRACTORY TO IMMUNE CHECKPOINT INHIBITOR | Sumitomo Pharma Co., Ltd. (JP) | 2025-11-20 | — | — | US | disclosed |
| US-12410154-B2 | 5-heteroaryl-1H-pyrazol-3-amine derivative | Sumitomo Pharma Co., Ltd. (JP) | 2025-09-09 | — | — | US | disclosed |
| US-12337036-B2 | Compounds and methods for trans-membrane delivery of molecules | APOSENSE LTD (IL) | 2025-06-24 | — | — | US | disclosed |
| EP-4534100-A1 | THERAPEUTIC FOR CANCER REFRACTORY TO IMMUNE CHECKPOINT INHIBITOR | Sumitomo Pharma Co., Ltd. (JP) | 2025-04-09 | — | — | EP | disclosed |
| US-20250025443-A1 | COMPOUNDS AND METHODS FOR TREATING CORONA VIRUSES | Clear Creek Bio, Inc. (US) | 2025-01-23 | — | — | US | disclosed |
| EP-4253377-A1 | 5-HETEROARYL-1H-PYRAZOL-3-AMINE DERIVATIVE | Sumitomo Pharma Co., Ltd. (JP) | 2023-10-04 | — | — | EP | disclosed |
| US-20230025065-A1 | 5-HETEROARYL-1H-PYRAZOL-3-AMINE DERIVATIVE | Sumitomo Pharma Co., Ltd. (JP) | 2023-01-26 | — | — | US | disclosed |
| US-20220378745-A1 | CHK1/2 INHIBITORS FOR USE IN THE TREATMENT OF NEUROBLASTOMAS AND/OR SOFT TISSUE SARCOMAS | ELI LILLY AND COMPANY | 2022-12-01 | — | — | US | disclosed |
| WO-2007143558-A1 | TARGETED NANOSTRUCTURES FOR CELLULAR IMAGING | WILLIAM MARSH RICE UNIVERSITY (US) | 2007-12-13 | — | — | WO | disclosed |
| US-20060286065-A1 | Releasable polymeric conjugates based on aliphatic biodegradable linkers | BELROSE PHARMA INC. | 2006-12-21 | — | — | US | disclosed |
| US-7122189-B2 | Releasable polymeric conjugates based on aliphatic biodegradable linkers | ENZON, INC. (US) | 2006-10-17 | — | — | US | disclosed |
| EP-1534334-A1 | RELEASABLE POLYMERIC CONJUGATES BASED ON ALIPHATIC BIODEGRADABLE LINKERS | ENZON, INC. (US) | 2005-06-01 | — | — | EP | disclosed |
| EP-1494757-A2 | POLYMERIC ACYL DERIVATIVES OF INDOLES | ENZON, INC. (US) | 2005-01-12 | — | — | EP | disclosed |
| US-20040037802-A1 | Releasable polymeric conjugates based on aliphatic biodegradable linkers | BELROSE PHARMA INC. | 2004-02-26 | — | — | US | disclosed |
| WO-2004014424-A1 | RELEASABLE POLYMERIC CONJUGATES BASED ON ALIPHATIC BIODEGRADABLE LINKERS | ENZON, INC. (US) | 2004-02-19 | — | — | WO | disclosed |
| WO-2004012506-A2 | ANTIMICROBIAL COMPOUNDS | EXEGENICS, INC. (US) | 2004-02-12 | — | — | WO | disclosed |
| US-6689794-B2 | SUPPRESSING MATRIX METALLOPROTEINASE AND/OR AGGRECANASE ACTIVITY | PHARMACIA CORPORATION | 2004-02-10 | — | — | US | disclosed |
| WO-2003084926-A2 | POLYMERIC ACYL DERIVATIVES OF INDOLES | ENZON, INC. (US) | 2003-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230025065-A1 | 5-HETEROARYL-1H-PYRAZOL-3-AMINE DERIVATIVE | CHEK1, CHEK2, RB1 | MEN1 2171/4885HTT 4612/4885KMT2A 478/4885 |
| US-20220378745-A1 | CHK1/2 INHIBITORS FOR USE IN THE TREATMENT OF NEUROBLASTOMAS AND/OR SOFT TISSUE SARCOMAS | CHEK1, CHEK2, PLK1 | MEN1 691/4885HTT 4495/4885KMT2A 491/4885 |
| US-20040037802-A1 | Releasable polymeric conjugates based on aliphatic biodegradable linkers | CD44, PAICS, PCBP1 | MEN1 3782/4885HTT 2583/4885KMT2A 2328/4885 |
| US-20260022109-A1 | 5-HETEROARYL-1H-PYRAZOL-3-AMINE DERIVATIVE | CHEK1, CHEK2, WEE1 | MEN1 1035/4885HTT 4686/4885KMT2A 671/4885 |
| US-20060286065-A1 | Releasable polymeric conjugates based on aliphatic biodegradable linkers | CD44, PAICS, PCBP1 | MEN1 3852/4885HTT 2327/4885KMT2A 2311/4885 |
| US-12410154-B2 | 5-heteroaryl-1H-pyrazol-3-amine derivative | CHEK1, CHEK2, RB1 | MEN1 2171/4885HTT 4612/4885KMT2A 478/4885 |
| US-12558345-B2 | CHK1/2 inhibitors for use in the treatment of neuroblastomas and/or soft tissue sarcomas | CHEK1, CHEK2, MRE11 | MEN1 953/4885HTT 2924/4885KMT2A 641/4885 |
| US-12337036-B2 | Compounds and methods for trans-membrane delivery of molecules | LDLR, NPC1L1, ABCB4 | MEN1 1858/4885HTT 1015/4885KMT2A 2787/4885 |
| US-20250025443-A1 | COMPOUNDS AND METHODS FOR TREATING CORONA VIRUSES | ACE, PREP, PEPD | MEN1 4188/4885HTT 2553/4885KMT2A 1791/4885 |
| US-20250352541-A1 | THERAPEUTIC FOR CANCER REFRACTORY TO IMMUNE CHECKPOINT INHIBITOR | CHEK1, CHEK2, PDCD1 | MEN1 1386/4885HTT 4779/4885KMT2A 282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.